Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes-a substudy of the TROPICAL-ACS trial.

András KomócsiBéla MerkelyMartin HadamitzkySteffen MassbergKonstantinos D RizasRalph Hein-RothweilerLisa GrossDietmar TrenkDirk Sibbing Dániel Aradi

Published in: European heart journal. Cardiovascular pharmacotherapy (2023)

The strategy of guided DAPT de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients.

Keyphrases

acute coronary syndrome
end stage renal disease
prognostic factors
ejection fraction
weight loss
physical activity
clinical trial
antiplatelet therapy
climate change
patient reported outcomes
body mass index
weight gain
phase ii
atrial fibrillation
percutaneous coronary intervention
double blind